Abstract: Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.
Abstract: The present invention is directed to the identification and isolation of a promoter region from a raspberry genome. The promoter is operably linked, in a native raspberry genome, to the coding region of a raspberry E4 gene. The raspberry E4 gene promoter of the invention is capable of regulating moderate level, constitutive expression of a heterologous plant gene under its control. The invention is further directed to chimeric genes, cassette vectors, kits, transgenic plants, and methods employing a raspberry E4 promoter.
Type:
Grant
Filed:
December 27, 1996
Date of Patent:
April 25, 2000
Assignee:
Agritope, Inc.
Inventors:
Richard K. Bestwick, Jill A. Kellogg, Helena V. Mathews
Abstract: Disclosed is a novel gene and growth arrest gene product encoded by the gene. Expression of the growth arrest gene B4B results in inhibition of cellular proliferation. The gene and gene product serve as markers of cancerous or pre-cancerous conditions, and as markers of immune states.
Type:
Grant
Filed:
June 27, 1997
Date of Patent:
December 7, 1999
Assignee:
Dendreon Corporation
Inventors:
Curtis L. Ruegg, Reiner Laus, Edgar G. Engleman
Abstract: Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.
Abstract: A method of treating or preventing post-operative ileus in a mammalian subject is disclosed. The method involves administering to the subject, a pharmaceutically effective amount of a compound that is effective in (i) preventing mast cell degranulation, (ii) inhibiting tryptase and chymase, and (iii) antagonizing PAR-2. The treatment is based on the discoveries that proteinase-activated receptor 2 is expressed in colonic muscle cells, and that activation of PAR-2 inhibits colonic motility. The PAR-2 receptor is activated, at least in part, by tryptase and chymase, produced by infiltration and degranulation of mast cells.
Type:
Grant
Filed:
March 27, 1998
Date of Patent:
September 28, 1999
Assignee:
The Regents of the Uinversity of California